Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14485151 | 0.78 | PSEN1 (0.41) | P2RX3LMNAMAPTALDH1A1POLB | |
| SCHEMBL15540674 | 0.71 | PTGS2 (0.50) | LMNAMAPTALDH1A1 | |
| SCHEMBL17645209 | 0.70 | AR (0.45) | PPARGP2RX3ALDH1A1POLB | |
| SCHEMBL14484808 | 0.67 | MCL1 (0.54) | LMNAMAPTALDH1A1 | |
| SCHEMBL16756469 | 0.66 | SMARCA2 (0.37) | PPARGP2RX3GRM5ALDH1A1 | |
| SCHEMBL17645416 | 0.66 | MCL1 (0.40) | PPARGLMNAMAPTALDH1A1POLB | |
| SCHEMBL15552719 | 0.66 | MCL1 (0.53) | LMNAMAPTALDH1A1 | |
| Lithium Ion SCHEMBL16756421 | 0.65 | RECQL (0.41) | PPARGPOLB | |
| SCHEMBL15829228 | 0.64 | CA12 (0.56) | POLB | |
| SCHEMBL22396926 | 0.63 | MAPT (0.47) | LMNAMAPTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828288-B2 | Hydrazone derivatives for the treatment of cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828288-B2 | Hydrazone derivatives for the treatment of cancer | H1-3, H1-5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PPARG 962/4885P2RX3 1644/4885GRM5 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.